Abstract

ANTI INFLAMMATORY EFFECT OF ALOGLIPTIN IN ISCHAEMIAREPERFUSION INDUCED CEREBRAL INFARCTION IN NORMAL AND STZ INDUCED TYPE-II DIABETIC RATS

K. Purnachander*, K. P. R. Chowdary and N. Kannappan

ABSTRACT

Type 2 Diabetes mellitus is an important risk factor for cerebral ischemic stroke. Oxidative stress in Type 2 Diabetes Mellitus causes irreversible neuronal damage during cerebral ischemic stroke. Free radicals cause oxidative stress and inflammation leading to increased injury in cerebral ischemia. Inflammation is the main culprit in cerebral ischemia/reperfusion injury. Alogliptin is the newer antidiabetic drug (DPP-4 inhibitor) is reported to have antiinflammatory action. The aim of the present study is to evaluate the antineuroinflammatory effect of Alogliptin against cerebral ischemia/reperfusion injury in normal and STZ induced diabetic rats. Bilateral common carotid artery occlusion (BCCAO) followed by 4 h reperfusion is the animal model used in the present study. Treatment with Alogliptin 30 mg/kg for a period of four weeks showed significant reduction in percent cerebral infarct volume. Alogliptin at 30 mg/kg dose also showed significant reduction in biomarkers like Myeloperoxidase, Tumor Necrosis Factor-α, Interleukin-6 (IL-6)and Interleukin-1β(IL-1β) in diabetic group when compared to normal group. Significant increase in IL-10 levels were observed in diabetic group when compared to normal group.

Keywords: cerebral ischemia/reperfusion injury, T2DM, Inflammation, Alogliptin.